DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 721, Issue 2, 2011, Pages 206-210

  Filippon, Letícia ^a,b   Wayhs, Carlos A Y ^b   Atik, Diana M ^b   Manfredini, Vanusa ^b,c   Herber, Silvani ^b   Carvalho, Clarissa G ^b   Schwartz, Ida V D ^b   Giugliani, Roberto ^b   Vargas, Carmen R ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

Author keywords

DNA damage; Enzyme replacement therapy; Lysosomal storage disease; Mucopolysaccharidosis type II; Oxidative stress

Indexed keywords

CARBONYL DERIVATIVE; IDURONATE 2 SULFATASE; MALONALDEHYDE;

ARTICLE; CELL PROTECTION; CHILD; CLINICAL ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; ENZYME REPLACEMENT; HUMAN; HUMAN CELL; HUNTER SYNDROME; LEUKOCYTE; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SILVER STAINING;

CHILD; CHILD, PRESCHOOL; DNA DAMAGE; ENZYME REPLACEMENT THERAPY; HUMANS; INFANT; LEUKOCYTES; MALE; MALONDIALDEHYDE; MUCOPOLYSACCHARIDOSIS II; PROTEIN CARBONYLATION;

EID: 79952814046     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2011.02.005     Document Type: Article

References (59)

1. Hunter C. A rare disease in two brothers. Proc. R. Soc. Med. 1917, 10:104-106.
2. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill, New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
3. Nelson J., Crowhurst J., Carey B., Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am. J. Med. Genet. Part A 2003, 123:310-313.
4. Baehner F., Schmiedeskamp C., Krummenauer F., Miebach E., Bajbouj M., Whybra C., Kohlschütter A., Kampmann C., Beck M. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J. Inherit. Metab. Dis. 2005, 28:1011-1017.
5. Poupětová H., Ledvinová J., Berná L., Dvořáková L., Kožich V., Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J. Inherit. Metab. Dis. 2010, 33:387-396.
6. Meikle P.J., Hopwood J.J., Claque A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
7. Pinto R., Caseiro C., Lemos M., Lopes L., Fontes A., Ribeiro H., Pinto E., Silva E., Rocha S., Marcao A., Ribeiro I., Lacerda L., Ribeiro G., Amaral O., Sa Miranda M.C. Prevalence of lysosomal storage diseases in Portugal. Eur. J. Hum. Genet. 2004, 12:87-92.
8. Vieira T., Schwartz I., Muñoz V., Pinto L., Steiner C., Ribeiro M., Boy R., Ferraz V., de Paula A., Kim C., Acosta A., Giugliani R. Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis?. Am. J. Med. Genet. Part A 2008, 146:1741-1747.
9. Coelho J.C., Wajner M., Burin M.G., Vargas C.R., Giugliani R. Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism. Eur. J. Pediatr. 1997, 156:650-654.
10. Martin R., Beck M., Eng C., Giugliani R., Harmatz P., Munoz V., Muenzer J. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008, 121:377-386.
11. Tuschl K., Gal A., Paschke E., Kircher S., Bodamer O.A. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr. Neurol. 2005, 32:270-272.
12. Vellodi A., Young E., Cooper A., Lidchi V., Winchester B., Wraith J.E. Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. 1999, 22:638-648.
13. Wraith J.E., Scarpa M., Beck M., Bodamer O.A., De Meirleir L., Guffon N., Lund A.M., Malm G., Van der Ploeg A.T., Zeman J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur. J. Pediatr. 2008, 167:267-277.
14. Muenzer J., Gucsavas-Calikoglu M., McCandless S.E., Schuetz T.J., Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol. Genet. Metab. 2007, 90:329-337.
15. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 2006, 8:465-473.
16. ® treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II). Mol. Genet. Metab. 2010, 99:18-25.
17. White K.K., Hale S., Goldberg M.J. Musculoskeletal health in Hunter disease (MPS II): ERT improves functional outcomes. J. Pediatr. Rehabil. Med. 2010, 3:101-107.
18. Sitta A., Barschak A.G., Deon M., Barden A.T., Biancini G.B., Vargas P.R., de Souza C.F., Netto C., Wajner M., Vargas C.R. Effect of short- and long-term exposition to high phenylalanine blood levels on oxidative damage in phenylketonuric patients. Int. J. Dev. Neurosci. 2009, 27:243-247.
19. Barschak A.G., Sitta A., Deon M., de Oliveira M.H., Haeser A., Dutra-Filho C.S., Wajner M., Vargas C.R. Evidence that oxidative stress is increased in plasma from patients with maple syrup urine disease. Metab. Brain Dis. 2006, 21:279-286.
20. Ribas G.S., Manfredini V., de Marco M.G., Vieira R.B., Wayhs C.Y., Vanzin C.S., Biancini G.B., Wajner M., Vargas C.R. Prevention by l-carnitine of DNA damage induced by propionic and l-methylmalonic acids in human peripheral leukocytes in vitro. Mutat. Res. 2010, 702:123-128.
21. Reolon G.K., Reinke A., Oliveira M.R., Braga L.M., Camassola M., Andrades M.E., Moreira J.C.F., Nardi N.B., Roesler R., Dal-Pizzol F. Alterations in oxidative markers in the cerebellum and peripheral organs in MPS I mice. Cell. Mol. Neurobiol. 2009, 29:443-448.
22. Pereira V.G., Martins A.M., Micheletti C., D'Almeida V. Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy. Clin. Chim. Acta 2007, 387:75-79.
23. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., Schuchman E.H. Molecular pathogenesis of genetic and inherited diseases mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 2008, 172:112-122.
24. Altarescu G., Zimran A., Michelakakis H., Elstein D. TNF-alpha levels and TNF-alpha gene polymorphism in type I Gaucher disease. Cytokine 2005, 31:149-152.
25. Altarescu G., Chicco G., Whybra C., Delgado-Sanchez S., Sharon N., Beck M., Elstein D. Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz severity score index for Fabry disease. J. Inherit. Metab. Dis. 2008, 31:117-123.
26. Jeyakumar M., Thomas R., Elliot-Smith E., Smith D.A., van der Spoel A.C., d'Azzo A., Perry V.H., Butters T.D., Dwek R.A., Platt F.M. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 2003, 126:974-987.
27. Jeyakumar M., Smith D.A., Williams I.M., Borja M.C., Neville D.C., Butters T.D., Dwek R.A., Platt F.M. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann. Neurol. 2004, 56:642-649.
28. Villani G.R.D., Gargiulo N., Faraonio R., Castaldo S., Reyero E.G., Di Natale P. Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J. Neurosci. Res. 2007, 85:612-622.
29. Ohmi K., Greenberg D.S., Rajavel K.S., Ryazantsev S., Li H.H., Neufeld E.F. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1902-1907.
30. Villani G.R.D., Di Domenico C., Musella A., Cecere F., Di Napoli D., Di Natale P. Mucopolysaccharidosis IIIB: oxidative damage and cytotoxic cell involvement in the neuronal pathogenesis. Brain Res. 2009, 1279:99-108.
31. de Jong J.G.N., Wevers R.A., Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin. Chem. 1992, 38:803-807.
32. Voznyi Y.V., Keulemans J.I.M., van Diggelen O.P. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J. Inherit. Metab. Dis. 2001, 24:675-680.
33. Esterbauer H., Cheeseman K.H. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990, 186:407-421.
34. Levine R.L., Garland D., Oliver C.N., Amici A., Climent L., Lenz A.G., Ahn B.W., Shalthiel S., Stadman E.R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990, 186:464-478.
35. Singh N., McCoy M., Tice R., Schneider E. A simple technique for quantification of low levels of DNA damage in individuals cells. Exp. Cell Res. 1988, 175:184-191.
36. Tice R.R., Agurell D., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., Sasaki Y.F. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 2000, 35:206-221.
37. Hartmann A., Agurell E., Beevers C., Brendler-Schwaab S., Burlinson B., Clay P., Collins A., Smith G., Speit G., Thybaud V., Tice R.R. Recommendations for conducting the in vivo alkaline comet assay. Mutagenesis 2003, 18:45-51.
38. Nadin S., Vargas-Roig L., Ciocca D. A silver staining method for single-cell gel assay. J. Histochem. Cytochem. 2001, 49:1183-1186.
39. Halliwell B., Gutteridge J.M.C. Oxidative stress: adaptation, damage, repair and death. Free Radicals in Biology and Medicine 1999, 246-350. Oxford University Press, New York. 3rd ed. B. Halliwell, J.M.C. Gutteridge (Eds.).
40. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 2007, Oxford University Press, New York. 4th ed.
41. Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
42. Reznick A.Z., Packer L. Free radicals and antioxidants in muscular neurological diseases and disorders. Free Radicals: From Basic Science to Medicine 1993, 425-437. Birkhäuser Verlag, Basel. G. Poli, E. Albano, M.U. Dianzani (Eds.).
43. Sitta A., Barschak A.G., Deon M., de Mari J.F., Barden A.T., Vanzin C.S., Biancini G.B., Schwartz I.V.D., Wajner M., Vargas C.R. l-Carnitine blood levels and oxidative stress in treated phenylketonuric patients. Cell. Mol. Neurobiol. 2009, 29:211-218.
44. Deon M., Sitta A., Barschak A.G., Coelho D.M., Pigatto M., Schmitt G.O., Jardim L.B., Giugliani R., Wajner M., Vargas C.R. Induction of lipid peroxidation and decrease of antioxidant defenses in symptomatic and asymptomatic patients with X-linked adrenoleukodystrophy. Int. J. Dev. Neurosci. 2007, 25:441-444.
45. Wajner M., Latini A., Wyse A.T., Dutra-Filho C.S. The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J. Inherit. Metab. Dis. 2004, 27:427-448.
46. Barschak A.G., Sitta A., Deon M., Barden A.T., Dutra-Filho C.S., Wajner M., Vargas C.R. Oxidative stress in plasma from maple syrup urine disease patients during treatment. Metab. Brain Dis. 2008, 23:71-80.
47. Latini A., Borba Rosa R., Scussiato K., Llesuy S., Belló-Klein A., Wajner M. 3-Hydroxyglutaric acid induces oxidative stress and decreases the antioxidant defences in cerebral cortex of young rats. Brain Res. 2002, 956:367-373.
48. Terman A., Kurz T., Gustafsson B., Brunk U.T. Lysosomal labilization. IUBMB Life 2006, 58:531-539.
49. Kurz T., Leake A., von Zglinicki T., Brunk U.T. Lysosomal redox-active iron is important for oxidative stress-induced DNA damage. Ann. N. Y. Acad. Sci. 2004, 1019:285-288.
50. D'Errico M., Parlanti E., Dogliotti E. Mechanism of oxidative DNA damage repair and relevance to human pathology. Mutat. Res. 2008, 659:4-14.
51. Liao W., McNutt M.A., Zhu W.G. The comet assay: a sensitive method for detecting DNA damage in individual cells. Methods 2009, 48:46-53.
52. Dalle-Donne I., Rossi R., Colombo R., Giustarini D., Milzani A. Biomarkers of oxidative damage in human disease. Clin. Chem. 2006, 52:601-623.
53. Halliwell B. Role of free radicals in the neurodegenerative diseases. Drugs Aging 2001, 18:685-716.
54. Cooke M.S., Olinski R., Evans M.D. Does measurement of oxidative damage to DNA have clinical significance?. Clin. Chim. Acta 2006, 365:30-49.
55. Altieri F., Grillo C., Maceroni M., Chichiarelli S. DNA damage and repair: from molecular mechanisms to health implications. Antioxid. Redox Signal. 2008, 10:891-937.
56. Speit G., Hartmann A. The contribution of excision repair to the DNA effects seen in the alkaline single cell gel test (comet assay). Mutagenesis 1995, 10:555-559.
57. Sitta A., Manfredini V., Biasi L., Treméa R., Schwartz I.V.D., Wajner M., Vargas C.R. Evidence that DNA damage is associated to phenylalanine blood levels in leukocytes from phenylketonuric patients. Mutat. Res. 2009, 679:13-16.
58. Matté C., Mackedanz V., Stefanello F.M., Scherer E.B.S., Andreazza A.C., Zanotto C., Moro A.M., Garcia S.C., Gonçalves C.A., Erdtmann B., Salvador M., Wyse A.T.S. Chronic hyperhomocysteinemia alters antioxidant defenses and increases DNA damage in brain and blood of rats: protective effect of folic acid. Neurochem. Int. 2009, 54:7-13.
59. Hamano K., Hayashi M., Shioda K., Fukatsu R., Mizutani S. Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue. Acta Neuropathol. 2008, 115:547-559.